Samospharma Limited has refuted claims of any association with Aveo Pharmaceutical Pvt. Ltd and Westfin Pharmaceutical Pvt. Ltd – two companies recently implicated in a BBC report on the sale of opioid pills in West Africa.
In a letter addressed to the Food and Drugs Authority (FDA) and signed by its Managing Director, Mr Eugene Boakye, Samospharma described the allegations as “baseless and damaging,” calling on the regulatory body to provide evidence or issue a public correction.
The company stressed that it had never engaged in fraudulent activities nor maintained any connections with the entities in question.
It also asked the FDA to conduct an internal review to prevent such errors in future.
Samospharma also pointed out what it described as a significant inaccuracy in the FDA’s communication.
The Authority had stated that Indiana Ophthalmics LLP was the manufacturer of Timonidin Eye Drops, an assertion the company dismissed as false.
It clarified that the eye drops were not produced by Indiana Ophthalmics LLP, despite the latter being a duly registered pharmaceutical company in India.
To substantiate its position, Samospharma attached supporting documents, including correspondence from Kilitch Drugs (India) Ltd—manufacturers of Timonidin Eye Drops and Samocef Injection—along with commercial invoices, FDA consignment documents, and a Bill of Entry from the GRA Customs Division detailing the importation of Prolatan (Latanoprost) Eye Drops in 2023.
The company reaffirmed its commitment to ethical business practices and regulatory compliance, expressing hope that the FDA would act responsibly to rectify the matter.
This development follows an earlier media report in which the FDA assured the public of stringent monitoring of pharmaceutical imports following the BBC’s investigative exposé.
The report detailed how certain pharmaceutical firms in India had been implicated in the illegal distribution of opioids in West Africa, prompting heightened scrutiny by regulatory bodies.
Samospharma’s latest statement seeks to clear its name amid growing concerns over the integrity of pharmaceutical supply chains in the sub-region.
The company reiterated its dedication to working collaboratively with the FDA to ensure the continued supply of quality pharmaceutical products to the Ghanaian public.
